Skip to main
BTMD

Biote Corp (BTMD) Stock Forecast & Price Target

Biote Corp (BTMD) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Biote is expected to have a prolonged time horizon to drive sustainable growth in doctor adds, procedures and AEBITDA due to negative procedure rev/KPIs. Unfavorable acceptance trends among clinics, practitioners, and patients may hinder the company's growth and profitability, as it largely relies on practitioner awareness and adoption of its practice-building platform and supplements. Additionally, practitioners' potential reluctance to change their medical treatment practices to incorporate Biote's offerings may impact their adoption of the Biote Method and supplements.

Bears say

Biote is facing several challenges, including risks associated with international expansion, a low valuation, and difficulties in acquiring and retaining new clinics. Furthermore, a heavy reliance on key personnel and uncertainties around their sales and technology platform may impact future growth and profitability. Additionally, potential risks such as economic, regulatory, and political factors, as well as inflation and data security breaches, may also have a negative impact on the company's performance.

Biote Corp (BTMD) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biote Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biote Corp (BTMD) Forecast

Analysts have given Biote Corp (BTMD) a Buy based on their latest research and market trends.

According to 3 analysts, Biote Corp (BTMD) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biote Corp (BTMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.